How standard is second-line cetuximab in recurrent or metastatic head and neck cancer in 2017?

Petr Szturz, Tanguy Y. Seiwert, Jan B. Vermorken

Research output: Contribution to journal › Comment/debate › peer-review

8 Scopus citations

Fingerprint

Dive into the research topics of 'How standard is second-line cetuximab in recurrent or metastatic head and neck cancer in 2017?'. Together they form a unique fingerprint.